Study shows low risk of CV events with alendronate treatment in patients with hip fracture

1280 Views

eMediNexus 21 May 2018

Alendronate significantly reduces the risk of cardiovascular events (incident myocardial infarction, stroke) and mortality in patients treated with the bisphosphonate following a hip fracture, says a study published online May 9, 2018 in the Journal of Bone and Mineral Research.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.